Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MNOV

MNOV - MediciNova Inc Stock Price, Fair Value and News

$1.80-0.04 (-2.17%)
Market Closed

20/100

MNOV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

MNOV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.49

Target 3M

$1.68

Target 6M

$1.58

MNOV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNOV Price Action

Last 7 days

7.1%

Last 30 days

40.6%

Last 90 days

51.3%

Trailing 12 Months

-9.1%

MNOV RSI Chart

MNOV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNOV Valuation

Market Cap

88.3M

Price/Earnings (Trailing)

-7.35

Price/Sales (Trailing)

63.42

EV/EBITDA

-4.03

Price/Free Cashflow

-7.92

MNOV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.49

Target 3M

$1.68

Target 6M

$1.58

MNOV Fundamentals

MNOV Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

-23.89%

Rev. Growth (Qtr)

4.89%

MNOV Earnings

Earnings (TTM)

-12.0M

Earnings Growth (Yr)

-6.95%

Earnings Growth (Qtr)

7.03%

MNOV Profitability

Operating Margin

100.00%

EBT Margin

-940.33%

Return on Equity

-27.32%

Return on Assets

-25.24%

Free Cashflow Yield

-12.63%

MNOV Investor Care

Diluted EPS (TTM)

-0.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.6M1.5M1.4M0
20241.7M1.7M1.7M1.7M
20231.3M1.6M1.8M1.8M
20223.2M2.4M1.6M809.7K
20217.4M8.7M9.9M4.0M
20206.6M7.0M6.6M6.2M
20191.7M1.7M1.8M6.5M
20187.8M5.7M3.6M1.5M
20172.6M5.0M7.5M9.9M
2016495.5K383.5K271.5K159.5K
20152.9M2.1M1.4M607.5K
20145.4M4.8M4.3M3.7M
20133.4M006.0M
2012000802.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About MediciNova Inc

MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
 CEO
 WEBSITEmedicinova.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13

MediciNova Inc Frequently Asked Questions

MNOV is the stock ticker symbol of MediciNova Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of MediciNova Inc is 88.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MNOV's fair value in chart for subscribers.

The fair value guage provides a quick view whether MNOV is over valued or under valued. Whether MediciNova Inc is cheap or expensive depends on the assumptions which impact MediciNova Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNOV.

As of Wed Jan 28 2026, MNOV's PE ratio (Price to Earnings) is -7.35 and Price to Sales (PS) ratio is 63.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNOV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, MediciNova Inc has provided -0.077 (multiply by 100 for percentage) rate of return.